TrxR/EGFR-IN-1

TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor. TrxR/EGFR-IN-1 is active against both Gefitinib (HY-50895) -sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. TrxR/EGFR-IN-1 promotes the degradation of GPX4 protein through autophagolysosomal and proteasomal pathways, leading to ferroptosis. In addition, TrxR/EGFR-IN-1 can induce endoplasmic reticulum stress and trigger immunogenic cell death. TrxR/EGFR-IN-1 can be used for the research of Gefitinib (HY-50895) -resistant lung cancer[1].

Product Specifications

CAS Number

[3038386-42-1]

UNSPSC

12352005

Target

Apoptosis; EGFR; Ferroptosis; TrxR

Related Pathways

Apoptosis; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

ClC1=C(F)C=CC(NC2=NC=NC3=C2C=C(OCC#C[Au][P]45CN6CN(CN(C6)C5)C4)C(OC)=C3)=C1

Molecular Formula

C24H24AuClFN6O2P

Molecular Weight

710.88

References & Citations

[1]Wang L, et al. Dual-Targeting TrxR-EGFR Alkynyl-Au (I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4. J Med Chem. 2025 Feb 19.